

Research article

Open Access

## Mutacin H-29B is identical to mutacin II (J-T8)

Guillaume Nicolas<sup>1</sup>, H el ene Morency<sup>1</sup>, Gis ele LaPointe<sup>2</sup> and Marc C Lavoie<sup>\*3</sup>

Address: <sup>1</sup>D epartement de Biochimie et Microbiologie, Facult e des Sciences et G enie, Universit e Laval, Quebec, Quebec, G1K 7P4, Canada, <sup>2</sup>Centre de Recherche en Sciences et Technologie du Lait (STELA), Institut des Nutraceutiques et des Aliments Fonctionnels (INAF), Facult e des Sciences de l'Agriculture et de l'Alimentation, Universit e Laval, Qu ebec, G1K 7P4, Canada and <sup>3</sup>Department of Biological and Chemical Sciences, Faculty of Pure and Applied Sciences, The University of the West Indies, Cave Hill Campus, Bridgetown, BB 11000, Barbados

Email: Guillaume Nicolas - guillaume.nicolas.1@ulaval.ca; H el ene Morency - helene.morency@bcm.ulaval.ca; Gis ele LaPointe - gisele.lapointe@aln.ulaval.ca; Marc C Lavoie\* - mlavoie@uwichill.edu.bb

\* Corresponding author

Published: 20 April 2006

Received: 15 March 2006

BMC Microbiology 2006, 6:36 doi:10.1186/1471-2180-6-36

Accepted: 20 April 2006

This article is available from: <http://www.biomedcentral.com/1471-2180/6/36>

  2006 Nicolas et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** *Streptococcus mutans* produces bacteriocins named mutacins. Studies of mutacins have always been hampered by the difficulties in obtaining active liquid preparations of these substances. Some of them were found to be lantibiotics, defined as bacterial ribosomally synthesised lanthionine-containing peptides with antimicrobial activity. The goal of this study was to produce and characterize a new mutacin from *S. mutans* strain 29B, as it shows a promising activity spectrum against current human pathogens.

**Results:** Mutacin H-29B, produced by *S. mutans* strain 29B, was purified by successive hydrophobic chromatography from a liquid preparation consisting of cheese whey permeate (6% w/v) supplemented with yeast extract (2%) and CaCO<sub>3</sub> (1%). Edman degradation revealed 24 amino acids identical to those of mutacin II (also known as J-T8). The molecular mass of the purified peptide was evaluated at 3246.08 ± 0.1 Da by MALDI-TOF MS.

**Conclusion:** A simple procedure for production and purification of mutacins along with its characterization is presented. Our results show that the amino acid sequence of mutacin H-29B is identical to the already known mutacin II (J-T8) over the first 24 residues. *S. mutans* strains of widely different origins may thus produce very similar bacteriocins.

### Background

Bacteriocins are ribosomally synthesised proteinaceous bactericidal substances produced by bacteria [1]. Mutacins are bacteriocins produced by *Streptococcus mutans* [2] that are active against Gram-positive and some Gram-negative bacteria [3,4]. To date, four types of mutacin have been described: the mono- or di-peptide lantibiotic and the mono- or di-peptide non-lantibiotic mutacin [5-8]. Lantibiotics contain unusual amino acids such as Lan, BM-Lan and dehydrated amino acid residues [9]. Posttranslational modification of the prepeptide

occurs through amino acid dehydration, formation of thioether bridges and cleavage of the leader peptide during transport outside of the cell [9].

We previously classified mutacin-producing strains into 24 groups (designated A to X) and 7 clusters according to their activity spectra against bacterial pathogens and their immunity towards other mutacins [10,4]. The strain 29B producing mutacin H-29B was found to be closely related in its activity spectrum with strain T8 which produces mutacin II (also known as J-T8) [4]. The DNA probe

designed to hybridize with the *mutA* gene of mutacin II (J-T8) also hybridised with the DNA of strain 29B [11]. We present here a simple procedure for production and purification of mutacin H-29B, along with its partial characterization. The results show that the amino acid sequence of mutacin H-29B is identical to that of mutacin II (J-T8) over the first 24 residues. *S. mutans* strains of widely different origins may thus produce similar bacteriocins.

## Results and discussion

### Thermostability and pH stability

The activity of crude preparations of mutacin H-29B, calculated at 6400 AU/ml (Table 1) at pH 4, was not reduced in boiling water (100°C) after 1 h or after autoclaving (121°C, 15 min), but lost 20% of its activity after 2 h at 100°C. All mutacin activity was retained at pH 2–4 after 24 h, but was reduced to 80% at pH 5–7, to 60% at pH 8–9, and to 30% at pH 9–12. These results are in agreement with previously published results obtained on the activity of the mutacin-producing strain *S. mutans* 29B [10].

### Purification and characterization of the mutacin H-29B

Purification of mutacin H-29B was achieved by means of three hydrophobic chromatography steps (Table 1). The final specific activity of the purified mutacin H-29B was  $6.4 \times 10^6$  AU/mg. As for mutacin II (J-T8) [12,13], the amino acid sequence of the purified mutacin H-29B was blocked at position 9 without alkaline ethanethiol treatment, indicating the presence of modified residues and the lantibiotic nature of mutacin H-29B. This N-terminal sequence was found to be identical to mutacin II (J-T8) [12]. Balakrishnan et al. [14] also reported that mutacin M 19 presents the same N-terminal amino acid sequence. The absence of methionine at the N-terminus suggests that mutacin H-29B may be processed from a precursor form, as reported for lantibiotics in general [9].

Edman degradation performed after alkaline ethanethiol derivatization [15] revealed a total of 24 amino acids. The complete sequence of mutacin H-29B confirms its identity with the mutacin II (J-T8). Modified amino acids were obtained in positions 10, 12, 15, and 19. A BMSEC signal seen as a doublet signal in cycle 10 indicates the presence of an Abu or a dhB [15]. A SEC signal was observed in positions 12, 15, and 19 during sequencing, which indi-

cate the presence of a dhA residue [15]. In each case, the SEC signal was not accompanied by a DSER signal. At this stage, we can not tell if the dhA or Abu residues are implicated or not in the formation of thioether bridges. A deamidation was also observed for the Asn and Gln in positions 1, 5 and 18, which can result from the treatment with alkaline ethanethiol. A Phe residue was observed as a minor amino acid in position 25, probably resulting from the carryover effect of the sequencing procedure.

Comparison of the mutacin H-29B sequence with known bacteriocins revealed the high levels of homology to group AII lantibiotics (Figure 1). However, the TCCS or TCC motif present at the C-terminus of other AII lantibiotics was not detected by Edman degradation for mutacin H-29B. The DNA sequence of the gene coding for mutacin H-29B will confirm whether the TCC motif is also present at the C-terminus of mutacin H-29B.

The molecular mass of mutacin H-29B determined by MALDI-TOF MS ( $3246.08 \pm 0.1$  Da) is closely related to the one estimated for mutacin II (J-T8) ( $3244.64 \pm 1.15$  Da) [13,16]. This strongly suggested that these two mutacins are identical, including the three terminal amino acids. Thus, the experimentally-demonstrated thioether bridge pattern of mutacin II (J-T8) [16] can be proposed for mutacin H-29B. These would consist of one BM-Lan bridge between the residues in positions 10 (Thr) and 15 (Cys), one Lan bridge between residues 12 (Ser) and 26 (Cys) as well as a second Lan bridge between residues 19 (Ser) and 27 (Cys).

Different strains can produce the same mutacin: *S. mutans* strains T8, isolated in Australia; UA96, isolated in Alabama, USA; and 29B, isolated in Quebec, Canada [10,17], produce mutacin II (J-T8) ([12,14], this paper); *S. mutans* strains CH43 and UA140 produce mutacin I [7,18]; and *S. mutans* JH 1140, isolated in Florida USA [19], and UA787, isolated in Alabama, USA [20], produce the same mutacin, that only differs from mutacin B-Ny266 by only two amino acids [5].

Genes coding for mutacin biosynthesis have all been located on the chromosome so far [7,8,18-22]. The mutacin II (J-T8) gene cluster has been identified and suc-

**Table 1: Purification of mutacin H-29B by hydrophobic chromatography.**

Step	Volume (mL)	Activity (AU/mL)	Total Protein (mg)	Total activity (AU. 10 <sup>3</sup> )	Specific activity (AU/mg)	Yield (%)	Purification (fold)
Culture supernatant	1250	6400	10000	8000	800	100	1
XAD-7 Amberlite	300	6400	97.5	1920	20000	24	25
Sep-Pak C <sub>18</sub>	95	12800	1.9	1216	$6.4 \times 10^5$	15.2	800
C <sub>18</sub> RP-HPLC	1	$6.4 \times 10^5$	0.1	640	$6.4 \times 10^6$	8	8000

successfully transferred to a non-producing strain by transformation [22]. Evolution of the mutacin-lantibiotics from a common ancestor and its propagation via mobile genetic elements is suggested by further observations. A silent transposase gene was reported in the upstream region of the genes coding for mutacin II (J-T8) production [22]. Yonezawa and Kuramitsu (2005) [8] also observed direct repeats sequences flanking the *Smb* locus with similarity to those of transposase genes directly downstream of the locus. Sequences flanking the *Smb* locus were found adjacent in the UA159 *S. mutans* genome (GenBank Accession No [AE014133](#)). Mutacin-lantibiotic coding genes could perhaps be transferred via mobile genetic elements.

## Conclusion

Mutacin (H-29B) was isolated from an active liquid culture of *S. mutans* strain isolated in Quebec (29B) and proved to be identical to a previously characterized mutacin II (alias J-T8). Mutacin-lantibiotic production by *S. mutans* seems to be widespread despite the fact that the reference genome strain for *S. mutans* (UA159) does not seem to produce any of the mutacin lantibiotics characterized to date.

## Methods

### Bacterial strains and media

*Streptococcus mutans* 29B was previously described in Parrot et al. [17] and *Micrococcus luteus* ATCC 272 was from the American Type Culture Collection (Manassas, VA, USA). They were routinely grown aerobically at 37°C in TSB (Difco laboratories, Detroit, MI, USA) supplemented with 0.3% of Yeast Extract (Becton Dickinson & Co., Cockeysville, MD) (TSBYE) or on TSA (Difco) plates enriched with 0.3% yeast extract (TSAYE).

### Mutacin production

An overnight preculture in TSBYE was used to inoculate (1%) 2 L of medium consisting of cheese whey permeate 6% (w/v) (kind gift from Agropur agroalimentaire Coop, Granby, QC, Canada) supplemented with 1% CaCO<sub>3</sub> (Anachemia, Montreal, QC, Canada) and 2% yeast extract (Institut Rosell Montreal, QC, Canada) (SWP). The culture was incubated 48 h at 37°C under aerobic conditions [23].

### Determination of inhibitory activity

Mutacin activity was determined as describe previously [5] with the following modification: 2-fold dilutions were prepared in acidified (pH 2) peptone water (0.5%) [23]. The specific activity of each preparation was expressed in AU/mg protein. Protein concentration was determined using the BioRad DC protein assay (BioRad, Mississauga, ON, Canada).

### Thermostability and pH stability

Crude mutacin (supernatant of SWP medium) was submitted to different pH conditions (pH 2 to pH 11) adjusted with 4 N HCl or 4 N NaOH. After 2 h and 24 h at room temperature, residual mutacin activity was assayed by the spot test described above. Non-inoculated sterile SWP medium adjusted in the same conditions of the tested sample was used as negative control. Thermostability was assayed by determining the residual activity of crude mutacin samples adjusted at pH 4 and placed in boiling water for up to 120 min and after autoclaving.

### Mutacin H-29B extraction and purification

After 48 h of incubation at 37°C, the pH of the culture was adjusted to 2.0 with 4 N HCl and incubated for 2 h at room temperature to desorb the mutacin [23]. The culture was then centrifuged at 10,000 × g for 10 min and heated at 70°C for 20 min to destroy the remaining cells and enzyme activity. The purification steps were essentially those previously used for the purification of mutacin B-Ny266 [5] with the following modification: concentration was carried out by adsorption to XAD-7 Amberlite (Sigma Chemical CO., St Louis, MO, USA). Hydrophobic chromatography on Sep-Pak® Vac 35 cc (10 g) t-C<sub>18</sub> Cartridges (Waters Corporation, Milford, MA, USA) was performed with the pooled active fractions diluted to 35% in MeOH in 10 mM HCl. Active fractions were recovered with an elution gradient of 50%–60% MeOH in 10 mM HCl. The final purification step was carried out by reverse phase chromatography (RP)-HPLC (Beckman Gold Model, Coulter Canada Inc., Mississauga, ON, Canada) using an analytical C<sub>18</sub> column (Luna 5 μ C18(2), 250 × 4.6 mm, 4 × 3.0 mm, Phenomenex, Torrance, CA, USA). Elution was carried out with 5% acetonitrile in 0.1% TFA and 60% acetonitrile in 0.1% TFA and recorded at 214 nm.

Several re-injections of the same sample were made until a unique peak was obtained. Active fractions were dried in a Speed-Vac® concentrator (Model SC110A, Savant Instrument Inc. Farmingdale, NY) and kept at -20°C for further analyses.

### Molecular mass determination

Molecular mass was determined for the purified HPLC fraction by MALDI-TOF MS on a Voyager DE-PRO (Applied Biosystems, Foster City, CA, USA) at the Peptide Synthesis & Protein Sequencing Core facility of Eastern Quebec, QC, Canada.

### Sequence determination

Automated Edman degradation was performed on a protein sequencer (ABI Procise cLC, Applied Biosystems, Foster City, CA, USA) after alkaline ethanethiol derivatization [15]. Pure mutacin B-Ny266 was used as control [5]. Homology searches were carried out with the National

```

mutacin H-29B      NRWWQGVVPTVSYECRMNSWQHVF---
mutacin II (J-T8) NRWWQGVVPTVSYECRMNSWQHVFTCC
lactacin 481      KG--GSGVIHTISHECHNMNSWQFVFTCCS
variacin          ---GSGVIPTISHECHMNSFQFVFTCCS
nukacin ISK-1     KK--KSGVIPTVSHDCHMNSFQFVFTCC
ruminococcin A   ---GNGVLKTISHECHNMNTWQFLFTCC
butyriovibriocin OR79A ---GDGVFRTISHECHMNTWMFIFTCCS
streptococcin A-FF22 G--KNGVFKTISHECHLNTWAFLATCCS
streptococcin A-M49 G--KNGVFKTISHECHLNTWAFLATCCS
streptococcin A-FF22' RG--HGV-NTISAECRWNSLQAIFTCC
salivaricin A    KR--GSGWIATIITDDCP-NS---VFVCC

```

### Figure 1

Multiple sequence alignment of mutacin H-29B with homologous type AII lantibiotics. Only propeptides are shown. Conserved amino acids are in bold-type. Bacteriocin ruminococcin A is produced by *Ruminococcus gnavus* [25], butyriovibriocin OR79A by *Butyriovibrio fibrisolvens* [26], salivaricin A by *Streptococcus salivarius* [27], lactacin 481 by *Lactococcus lactis* [28], variacin by *Micrococcus varians* [29], nukacin ISK-1 by *Staphylococcus warneri* [30], mutacin II (J-T8) [16], and streptococcin A-M49, A-FF22 and A-FF22' are produced by *Streptococcus pyogenes* [31, 32].

Center of Biotechnology Information (rps-BLAST search, with Expect value = 0.01 and Search mode = multiple hits, 1 pass) [24].

### Protein sequence accession number

The protein sequence data of mutacin H-29B appears in the Swiss-Prot and TrEMBL knowledgebase under the accession number P84110.

### Abbreviations

Abu, 2-aminobutyric acid; ATCC, American Type Culture Collection; AU, arbitrary units; BM-Lan,  $\beta$ -methylanthionine; BMSEC,  $\beta$ -methyl-S-ethylcysteine; dhA, 2,3-didehydroalanine; dhB, 2,3-didehydrobutyrine; DSER, PTH-dithiothreitol adduct of dhA; Lan, lanthionine; MALDI-TOF MS, Matrix Assisted Laser Desorption Ionisation-Time of Flight Mass Spectroscopy; PTH, phenylthiohydantoin; RP-HPLC, reverse-phase high-pressure liquid chromatography; SEC, S-ethylcysteine; TFA, trifluoroacetic acid; TSAYE, trypticase soy agar yeast extract; TSBYE, trypticase soy broth yeast extract.

### Authors' contributions

Guillaume Nicolas participated in project conception, is the main manipulator of the experiments, evaluated MS and sequencing data and drafted the manuscript. Helene Morency participated in the purification of the peptide mutacin H-29B. Gisèle LaPointe designed and supervised the molecular analyses and participated in manuscript preparation. Marc C. Lavoie conceived the study and participated in its design and coordination as well as manuscript preparation. All authors read and approved the final manuscript.

### Acknowledgements

This work was supported by the Natural Sciences and Engineering Research Council of Canada. We thank Laurent Smith of the Department of Biochemistry and Microbiology and Alain Gaudreau of INAF (Nutraceuticals and Functional Foods Institute) and the STELA Dairy Research Group of Université Laval for their technical assistance.

### References

1. Jack RW, Tagg JR, Ray B: **Bacteriocin of Gram-positive bacteria.** *Microbiol Rev* 1995, **59**:171-200.
2. Hamada S, Ooshima T: **Production and properties of bacteriocins (mutacins) from *Streptococcus mutans*.** *Archs Oral Biol* 1975, **20**:641-648.
3. Mota-Meira M, LaPointe G, Lacroix C, Lavoie MC: **MICs of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against bacterial pathogens.** *Antimicrob Agents Chemother* 2000, **44**:24-29.
4. Morency H, Mota-Meira M, LaPointe G, Lacroix C, Lavoie MC: **Comparison of the activity spectra against pathogens of bacterial strains producing a mutacin or a lantibiotic.** *Can J Microbiol* 2001, **47**:322-331.
5. Mota-Meira M, Lacroix C, LaPointe G, Lavoie MC: **Purification and structure of the mutacin B-Ny266: a new lantibiotic produced by *Streptococcus mutans*.** *FEBS Letters* 1997, **410**:275-279.
6. Balakrishnan M, Simmonds RS, Carne A, Tagg JR: ***Streptococcus mutans* strain N produces a novel low molecular mass non-lantibiotic bacteriocin.** *FEMS Microbiol Lett* 2000, **183**:165-169.
7. Qi F, Chen P, Caufield PW: **The group I strain of *Streptococcus mutans*, UA140, produces both the lantibiotic mutacin I and a nonlantibiotic bacteriocin, mutacin IV.** *Appl Environ Microbiol* 2001, **67**:15-21.
8. Yonezawa H, Kuramitsu HK: **Genetic analysis of a unique bacteriocin, Smb, produced by *Streptococcus mutans* GS5.** *Antimicrob Agents Chemother* 2005, **49**:541-548.
9. McAuliffe O, Ross RP, Hill C: **Lantibiotics: structure, biosynthesis and mode of action.** *FEMS Microbiol Rev* 2001, **25**:285-308.
10. Morency H, Trahan L, Lavoie MC: **Preliminary grouping of mutacins.** *Can J Microbiol* 1995, **41**:826-831.
11. Bekal-Si Ali S, Hurtubise Y, Lavoie MC, LaPointe G: **Diversity of *Streptococcus mutans* bacteriocins as confirmed by DNA analysis using specific molecular probes.** *Gene* 2002, **283**:125-131.
12. Novak J, Bourgeau G, Caufield PW, Parrot M, Norkates J, Lavoie M, Miller E: **Biochemical analysis of a group II mutacin from *Streptococcus mutans*.** *Abstract of the ASM General Meeting No. A-44* 1993:8.
13. Novak J, Caufield PW, Miller EJ: **Isolation and biochemical characterization of a novel lantibiotic mutacin from *Streptococcus mutans*.** *J Bacteriol* 1994, **176**:4316-4320.
14. Balakrishnan M, Simmonds RS, Killian M, Tagg JR: **Different bacteriocin activities of *Streptococcus mutans* reflect distinct phylogenetic lineages.** *J Med Microbiol* 2002, **51**:941-948.
15. Meyer HE, Heber M, Eisermann B, Korte H, Metzger JW, Jung G: **Sequence analysis of lantibiotics: chemical derivatization procedures allow a fast access to complete Edman degradation.** *Anal Biochem* 1994, **223**:185-190.
16. Krull RE, Chen P, Novak J, Kirk M, Barnes S, Baker J, Krishna NR, Caufield PW: **Biochemical structural analysis of the lantibiotic mutacin II.** *J Biol Chem* 2000, **275**:15848-15850.
17. Parrot M, Caufield PW, Lavoie MC: **Production of mutacin-like substances by *Streptococcus mutans*.** *Can J Microbiol* 1989, **36**:123-130.
18. Qi F, Chen P, Caufield PW: **Purification and biochemical characterization of mutacin I from group I strain of *Streptococcus mutans*, CH43, and genetic analysis of mutacin I biosynthesis genes.** *Appl Environ Microbiol* 2000, **66**:3221-3229.
19. Hillman JD, Novak J, Sagura E, Gutierrez JA, Brooks A, Crowley PJ, Hess M, Azizi A, Leung K-P, Cvitkovitch D, Bleiweis AS: **Genetic and biochemical analysis of mutacin I140, a lantibiotic from *Streptococcus mutans*.** *Infect Immun* 1998, **66**:2743-2749.
20. Qi F, Chen P, Caufield PW: **Purification of mutacin III from group III *Streptococcus mutans* UA787 and genetic analyses of mutacin III biosynthesis genes.** *Appl Environ Microbiol* 1999, **65**:3880-3887.

21. Woodruff WA, Novak J, Caufield PW: **Sequence analysis of *mutA* and *mutM* genes involved in the biosynthesis of the lantibiotic mutacin II in *Streptococcus mutans*.** *Gene* 1998, **206**:37-43.
22. Chen P, Qi F, Novak J, Caufield PW: **The specific genes for lantibiotic mutacin II biosynthesis in *Streptococcus mutans* T8 are clustered and can be transferred en bloc.** *Appl Environ Microbiol* 1999, **65**:1356-1360.
23. Nicolas G, Auger I, Beaudoin M, Halle F, Morency H, LaPointe G, Lavoie MC: **Improved methods for mutacin detection and production.** *J Microbiol Methods* 2004, **59**:351-361.
24. Marchler-Bauer A, Anderson JB, DeWeese-Scott C, Fedorova ND, Geer LY, He S, Hurwitz DI, Jackson JD, Jacobs AR, Lanczycki CJ, Liebert CA, Liu C, Madej T, Marchler GH, Mazumder R, Nikolskaya AN, Panchenko AR, Rao BS, Shoemaker BA, Simonyan V, Song JS, Thiessen PA, Vasudevan S, Wang Y, Yamashita RA, Yin JJ, Bryant SH: **CDD: a curated Entrez database of conserved domain alignments.** *Nucleic Acids Res* 2003, **31**:383-387.
25. Dabard J, Bridonneau C, Phillippe C, Anglade P, Molle D, Nardi M, Ladiré M, Girardin H, Marcille F, Gomez A, Fons M: **Ruminococcin A, a new lantibiotic produced by a *Ruminococcus gnavus* strain isolated from human feces.** *Appl Environ Microbiol* 2001, **67**:4111-4118.
26. Kalmokoff ML, Lu D, Whitford MF, Teather RM: **Evidence for production of a new lantibiotic (butyrivibriocin OR79A) by the ruminal anaerobe *Butyrivibrio fibrisolvens* OR79: characterization of the structural gene encoding butyrivibriocin OR79A.** *Appl Environ Microbiol* 1999, **65**:2128-2135.
27. Ross KF, Ronson CW, Tagg JR: **Isolation and characterization of the lantibiotic salivaricin A and its structural gene *salA* from *Streptococcus salivarius* 20P3.** *Appl Environ Microbiol* 1993, **59**:2014-2021.
28. Piard JC, Kuipers OP, Rollema HS, Desmazeaud MJ, de Vos WM: **Structure, organization, and expression of the *lct* gene for lactacin 481, a novel lantibiotic produced by *Lactococcus lactis*.** *J Biol Chem* 1993, **268**:16361-16368.
29. Pridmore D, Rekhif N, Pittet AC, Suri B, Mollet B: **Variacin, a new lanthionin-containing bacteriocin produced by *Micrococcus varians*: comparison to lactacin 481 of *Lactococcus lactis*.** *Appl Environ Microbiol* 1996, **62**:1799-1802.
30. Sashihara T, Kimura H, Higuchi T, Adachi A, Matsusaki H, Sonomoto K, Ishizaki A: **Cloning of the gene encoding a novel lantibiotic, nukacin ISK-1, of *Staphylococcus wamerei*.** *J Fac Agr Kyushu Univ* 2000, **45**:149-161.
31. Hynes WL, Ferretti JJ, Tagg JR: **Cloning of the gene encoding streptococcin A-FF22, a novel lantibiotic produced by *Streptococcus pyogenes*, and determination of its nucleotide sequence.** *Appl Environ Microbiol* 1993, **59**:1969-1971.
32. Hynes WL, Friend VL, Ferretti JJ: **Duplication of the lantibiotic structural gene in M-type 49 group A *Streptococcus* strains producing streptococcin A-M49.** *Appl Environ Microbiol* 1994, **60**:4207-4209.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

